Full access to Entrepreneur for $5
Subscribe

Why Buckle (BKE) Stock Might be a Great Pick

Buckle (BKE) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.

By
This story originally appeared on Zacks

One stock that might be an intriguing choice for investors right now is The Buckle, Inc. BKE. This is because this security in the Retail - Apparel and Shoes space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.

- Zacks

This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Retail - Apparel and Shoes space as it currently has a Zacks Industry Rank of 39 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.

Meanwhile, Buckle is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past two months, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.

In fact, over the past two months, current quarter estimates have risen from 71 cents share to 76 cents per share, while current year estimates have risen from $3.75 per share to $4.24 per share.  This has helped BKE to earn a Zacks Rank #2 (Buy), further underscoring the company’s solid position.  You can see the complete list of today’s Zacks #1(Strong Buy) Rank stocks here.

So, if you are looking for a decent pick in a strong industry, consider Buckle. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.

 



Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>



Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 

Buckle, Inc. The (BKE): Free Stock Analysis Report

 

To read this article on Zacks.com click here.

 

Zacks Investment Research